Post-LASIK contact lens launched

Article

A hybrid contact lens designed for eyes that have suffered corneal trauma or undergone either refractive surgery or penetrating keratoplasty has been launched by SynergEyes Inc, US. The SynergEyes PS lens can also be used in eyes with degenerative corneal conditions.

A hybrid contact lens designed for eyes that have suffered corneal trauma or undergone either refractive surgery or penetrating keratoplasty has been launched by SynergEyes Inc, US. The SynergEyes PS lens can also be used in eyes with degenerative corneal conditions.

The rigid gas permeable centre of the SynergEyes PS lens and the soft outer skirt combine to offer a viable solution to ghosting, haloes, blurry vision and dryness in post-surgical eyes.

SynergEyes also has FDA clearance on contact lenses for the treatment of ametropia, astigmatism, keratoconus and presbyopia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.